Replies to post #1508 on Conatus Pharmaceuticals Inc. (CNAT)

[lorema]

I think they have other compounds they like to develop! We will know more when all the legal stuff for the Novartis deal is done.

[lorema]

Steve Mento on the latest conference call, "What we provided at Neetham Conference were some examples of retained compounds, caspase inhibitors other then emricasan that showed activity in preclinical models or brain disease, of other aspects of liver disease not related to NASH, cardiovascular disease and lung disease; so pick your organ. Depending on the disease there is potential for caspase activity to be contributing to the disease and caspase inhibition to be a potential efficacy related to that disease. "